Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot of afatinib with intermittent osimertinib triggered by cfDNA-detected T790M in first-line EGFR-mutant NSCLC
MOH_2020-05-17_008947Phase 2Not yet recruiting
- Sponsor
- פרופ ניר פלד
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and osimertinib in non-small cell lung cancer (NSCLC), sponsored by פרופ ניר פלד. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-05-17_008947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-17_008947.